Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 13Thoracic 7Gastrointestinal 7Tumor-Agnostic 6Genitourinary 6Gynecologic 5Other hematologic neoplasm 3Head & Neck 3CNS 3Lymphoid 2Dermatologic 2Plasma cell 1Other 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasms 1Melanoma 1Health Behavior 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Focus Groups × Dermatologic × Clear all
NCT04118062 2025-09-19

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Institut Curie

Phase NA Completed
128 enrolled
BreastDermatologic

Uveal Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00518050 2015-07-16

Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns

Memorial Sloan Kettering Cancer Center

Completed
160 enrolled
Dermatologic

Melanoma, Health Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡